Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Northwest Biotherapeutics (NWBO) just unveiled an announcement.
Pat Sarma has been appointed as a Class II director and member of the Audit, Compensation, and Conflicts Committees, effective March 18, 2024. His appointment came with no prior arrangements and is free from any related-party transactions requiring disclosure. As an independent director, Sarma will receive the same compensation as other non-employee directors of the company.
For detailed information about NWBO stock, go to TipRanks’ Stock Analysis page.

